<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02792946</url>
  </required_header>
  <id_info>
    <org_study_id>HT-002-05</org_study_id>
    <nct_id>NCT02792946</nct_id>
  </id_info>
  <brief_title>Compare the Efficacy and Safety of Surfolase CR Tablet With Surfolase Capsule in Patients With Acute Bronchitis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hyundai Pharmaceutical Co., LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hyundai Pharmaceutical Co., LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the efficacy and safety of surfolase CR tablet with surfolate capsule in patients
      with acute bronchitis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in baseline to Day 7 for total number of Bronchitis Severity Score (BSS)</measure>
    <time_frame>Baseline, At Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in baseline to Day 7 for number of BSS per symptom</measure>
    <time_frame>Baseline, At Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate at Day 7</measure>
    <time_frame>Baseline, At Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">244</enrollment>
  <condition>Acute Bronchitis</condition>
  <arm_group>
    <arm_group_label>Sulfolase CR (200mg, QD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>for 7 days with or without meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sulfolase Capsule (100mg, BID)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>for 7 days with or without meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acebrophylline</intervention_name>
    <arm_group_label>Sulfolase CR (200mg, QD)</arm_group_label>
    <arm_group_label>Sulfolase Capsule (100mg, BID)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged 19 to 65 years, inclusive

          2. Patients with acute bronchitis which is accompanied with a cough which includes sputum
             within 48 hours and has over 5 for Bronchitis severity score (BSS) at Screening

          3. Patients who agreed to participate clinical trial and sign on informed consent form

        Exclusion Criteria:

          1. Patients who are suspicious or diagnosed for pneumonia

          2. Patients with chronic bronchitis, Chronic Obstructive Pulmonary Disease (COPD),
             bronchiolitis, asthma, bronchial asthma

          3. Patients with active infection who needs administration of antibiotics

          4. Patients with myocardial infarction, congestive heart failure

          5. Patients with renal disorder or liver disorder

          6. Patients with hypotension or hypertension

          7. Patients with history of epilepsy

          8. Patients with hyperthyroidism

          9. Patients with gastroduodenal ulcer

         10. Patients with sever hypoxemia

         11. Patients who are in drug or therapy or planned to have;

               -  antibiotics, anti-virus, angiotensin converting enzyme (ACE) inhibitor and
                  systemic or inhalation glucocorticosteroids: from 2 weeks prior to administration
                  of investigational product to termination of clinical trial

               -  Angiotension II receptor blocker (ARB), secretolytics/mucolytics, expectorants,
                  antitussives, a herb medicines which has antitussive or expectorant effect: from
                  2 days prior to administration of investigational product to termination of
                  clinical trial

               -  Analgesics except acetaminophen, antihistamines, Î²2-agonists, bronchodilators
                  which includes anticholinergic agents, xanthine derivatives, central nervous
                  system stimulants, drug which is known for interaction between acebrophylline
                  (cimetidine, alloprinol, oral anticoagulants, furosemide, reserpine,
                  barbiturates, phenytoin) and symtomatic therapy for other therapy for acute
                  bronchitis: whole period for clinical trial

         12. Smokers

         13. Patients who has history for drug hypersensitivity or allergic reaction in component
             of investigational product or similar drug

         14. Patients with pregnant and/or have breast feeding.

         15. Patients with no intention to use appropriate contraceptives or has a plan to become
             pregnant

         16. Patients who had an administrationb of other investigational product or medical device
             for clinical trial 4 weeks prior to participation of clinical trial

         17. Patients who are identified as inappropriate by other investigators to participate
             clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2016</study_first_submitted>
  <study_first_submitted_qc>June 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2016</study_first_posted>
  <last_update_submitted>June 15, 2017</last_update_submitted>
  <last_update_submitted_qc>June 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

